About InVivoSIM anti-respiratory syncytial virus (RSV) F protein (Nirsevimab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Nirsevimab, making it ideal for research use. Nirsevimab is a human IgG1 monoclonal antibody that targets the fusion (F) glycoprotein of respiratory syncytial virus (RSV), a highly contagious virus that causes serious respiratory infections, particularly in infants and older adults. The RSV F protein plays a critical role in viral entry by mediating the fusion of viral and host cell membranes, making it a key target for neutralization. Nirsevimab binds to a highly conserved epitope on the prefusion conformation of the RSV F protein, thereby preventing the conformational changes required for membrane fusion and subsequent infection. Unlike palivizumab, which binds both pre- and postfusion forms, Nirsevimab is specific to the prefusion form, enabling higher potency and prolonged protection. This Nirsevimab biosimilar is ideal for studying RSV entry mechanisms, neutralizing antibody responses, and RSV vaccine or therapeutic development. InVivoSIM anti-respiratory syncytial virus (RSV) F protein (Nirsevimab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenRSV F protein Reported ApplicationsIn vivo functional assays in vitro functional assays Flow cytometry ELISA FormulationpH 7.0 Contains no stabilizers or preservatives Endotoxin≤0.5EU/mg (≤0.0005EU/μg)Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity≥95%Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
